NA
Nautilus Biotechnolgy, Inc.
NAUT · NASDAQ
$0.95 +2.88% (+$0.03)
1M +9.07%
Market Cap $121.5M
P/E Ratio -
Div. Yield -
ROE 37.58%
Bulios Fair Price
$0.49
48.7% downside
Current Price
$0.95
Undervalued Fair Value Overvalued
According to Bulios Fair Price, NAUT is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
50 /100
Fair P/B 0.93x
P/S 639.42x
P/FFO N/A
Growth
0 /100
Declining Book val. growth 20.71%
FCF growth N/A
EPS growth N/A
Profitability
0 /100
Weak Op. margin 33,043.70%
Gross margin 919.47%
FCF margin 27,295.30%
Quality
0 /100
Poor ROA 34.55%
ROIC 39.50%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 10.14x
Debt/Equity 0.21x
Debt/Assets N/A
Stability
79 /100
Stable Profitable years 0
Beta 0.87x
EPS volatility 15.26%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NAUT
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Sujal Patel
Employees
127
Headquarters
Seattle
Upcoming events
27 OCT
Earnings
Upcoming earnings report